Probiotical cell fragments (PCFs) are structural components of the probiotic cell lysate(s) and exhibit similar beneficial effects on the host as live probiotic bacteria. With cell fragment technology (CFT?), the stru...Probiotical cell fragments (PCFs) are structural components of the probiotic cell lysate(s) and exhibit similar beneficial effects on the host as live probiotic bacteria. With cell fragment technology (CFT?), the structural fragments are isolated and purified from live probiotic cells. While observed to be strain-dependent as in the case of live probiotics, orally administered PCFs demonstrated a broad spectrum of immune modulation functions;anti-allergy;anti-inflammation;anti-bacterial and anti-viral properties;anti-mutagenic;and radioprotective and detoxification abilities in humans and animals. The PCFs mechanisms of action include events of motifs of cell wall peptidoglycans, DNA motifs, nucleotide containing components, lipoteichoic acids (LPAs), surface layer (S-layer) proteins, and cytoplasmic proteins. Different immunological in vivo-in vitro tests have shown that PCFs, essentially, have the ability to stimulate the macrophages, and induce cytokines such as interleukins, tumor necrosis factors (TNFs), interferons (IFNs), and natural killer (NK) cells. PCFs may be used as ingredients for foods and beverages or as nutritional supplements with long term stability and shelf-life up to 5 years. PCFs may also be used as health restorative ingredients in cosmetic products. The outcome of probiotics CFT? stands as an advantage to the food and pharmaceutical industries, regarding the formulation of novel products with unadulterated sensory characteristics of origin. Hence, PCFs are being characterized here as “novel nutraceutical ingredients” for health maintenance in both humans and animals.展开更多
The evidence in this paper indicates that the alarming increase of common allergies can be reduced by the intake of particular “probiotics” or “paraprobiotics” along with food. This appears to build a consensus in...The evidence in this paper indicates that the alarming increase of common allergies can be reduced by the intake of particular “probiotics” or “paraprobiotics” along with food. This appears to build a consensus in the pharmaceutical and food communities about the role of probiotics in the prevention and treatments of common allergies. Food allergy is one of the common allergies, defined as an adverse health effect arising from a specific immune response that occurs reproducibly on exposure to a given food. Improving the digestion of foods and maintaining a healthy gastrointestinal (GI) tract is certainly critical to controlling food allergens. Therefore, the association between a leaky gut or an impaired intestinal permeability and food-allergenic reactions is explained. Gluten has been found to be somehow a justification for protein allergy, and should, therefore, be avoided by people with celiac disease. In several, in vitro models, surface layer (S- layer) proteins of selective paraprobiotics have shown potential in alleviating food allergies and intestinal disorders. Notably, lactobacilli paraprobiotics have proven to be the immediate immunomodulators against common allergies and other diseases, including viral (flu, hepatitis C), bacterial (bronchitis), asthma, chronic fatigue, fibromyalgia, gastrointestinal distress, and autism disorders in humans.展开更多
The interplay between gut microbiota and host health has attracted significant interest in the animal science community.Maintaining gut microbiota homeostasis by supplementing probiotics to treat clinical conditions l...The interplay between gut microbiota and host health has attracted significant interest in the animal science community.Maintaining gut microbiota homeostasis by supplementing probiotics to treat clinical conditions like calf diarrhea is an emerging area of research nowadays because of increased concerns regarding antimicrobial resistance(AMR)and drug residues in animal products.Probiotics reduce the incidence of calf diarrhea by increasing the gut microbiota diversity and richness with more commensal bacteria such as Lactobacillus and Bifidobacterium that produce antimicrobial compounds,as well as modulating the immune response by increasing cytokines,Interleukin-2(IL-2),IL-4,IL-6,IL-10,and reducing tumor necrosis factor-α(TNF-α),by increasing production of antibodies,especially immunoglobulin E(Ig E),also Ig G,differentiating naive Th lymphocytes(Tho)into Th1,hence stimulate innate immunity and prime the adaptive immune response.Specific probiotic strains of bacteria and yeast(Saccharomyces cerevisiae)derived probiotics maintain the integrity of the intestinal barrier.In this review,data are being organized to address the role of probiotics in treating calf diarrhea by modulating gut microbiota and stimulating an immune response against notorious pathogens,to present animal and veterinary scientists and nutritionists with a new concept to treat infectious diseases from the perspective of the gut microbiota,increasing animal health,performance,and welfare.In conclusion,health status and gut microbiome are strongly interlinked.Research data indicated a significant reduction in the incidence of diarrhea after probiotic administration.If interrelations between probiotics and existing gut microbiota are explored more quantitatively,novel antibiotic substitutes can emerge in the future.展开更多
The mechanisms leading to neurological and neurodegenerative diseases are not completely known,and new,more effective,therapeutic treatments are necessary for most neurological pathologies.The treatment of neurologica...The mechanisms leading to neurological and neurodegenerative diseases are not completely known,and new,more effective,therapeutic treatments are necessary for most neurological pathologies.The treatment of neurological and neurodegenerative diseases is complicated due to the blood-brain barrier,which makes it difficult for drugs to access the brain areas in which they must act to improve the pathology.A tool that can help to overcome this difficulty is the use of extracellular vesicles,which can easily cross the blood-brain barrier.The extracellular vesicles are considered a main way of communication between the brain and the rest of the body,with important implications for the physiopathology and therapy of neurological diseases.In recent years,the involvement of microbiota in many neurological pathologies,as well as its possible therapeutic role,has also become evident.A key mediator in the pathologic and beneficial effects of microbiota seems to be the bacterial extracellular vesicles.There is an important communication between the brain and the intestinal microbiota(the gut-brain axis),by which the microbiota influences brain function,impacts on mental health,and plays a role in different neurological and neurodegenerative diseases.The identification of the mechanisms involved in this gut-brain axis is essential to understanding the mechanisms of neurological pathologies and to developing more effective treatments for these diseases.Bacterial extracellular vesicles would play a relevant role in these processes.This review compiles the recent information and evidence on the role of bacterial extracellular vesicles in brain pathologies and on the therapeutic utility of bacterial extracellular vesicles in neurological and neurodegenerative diseases.One advantage of bacterial extracellular vesicles compared to extracellular vesicles derived from other cell types,such as stem cells,is that bacterial extracellular vesicles are generally easier to produce and modify.Bacterial extracellular vesicles may be easily modified to target a specific pathology and/or to enhance its therapeutic efficacy.Although the studies are still scarce,they open a wide field of possibilities for future studies,which will lead to a deeper understanding of the role of microbiota and bacterial extracellular vesicles in neurological pathologies and the underlying mechanisms,as well as to the development of new treatments based on the use of bacterial extracellular vesicles in neurological diseases.展开更多
Parkinson’s disease is characterized by synucleinopathy-associated neurodegeneration.Previous studies have shown that glucagon-like peptide-1(GLP-1)has beneficial effects in a mouse model of Parkinson’s disease indu...Parkinson’s disease is characterized by synucleinopathy-associated neurodegeneration.Previous studies have shown that glucagon-like peptide-1(GLP-1)has beneficial effects in a mouse model of Parkinson’s disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.However,the effect of GLP-1 on intrinsic synuclein malfunction remains unclear.In this study,we investigated the effect of Lactococcus lactis MG1363-pMG36e-GLP-1 on parkinsonism in SncaA53T transgenic mice and explored the underlying mechanisms.Our data showed that Lactococcus lactis MG1363-pMG36e-GLP-1 inhibited dopaminergic neuronal death,reduced pathological aggregation ofα-synuclein,and decreased movement disorders in SncaA53T transgenic mice.Furthermore,Lactococcus lactis MG1363-pMG36e-GLP-1 downregulated lipopolysaccharide-related inflammation,reduced cerebral activation of microglia and astrocytes,and promoted cell survival via the GLP-1 receptor/PI3K/Akt pathway in the substantia nigra.Additionally,Lactococcus lactis MG1363-pMG36e-GLP-1 decreased serum levels of pro-inflammatory molecules including lipopolysaccharide,lipopolysaccharide binding protein,interleukin-1β,and interleukin-6.Gut histopathology and western blotting further revealed that Lactococcus lactis MG1363-pMG36e-GLP-1 increased the expression of gut integrity-related proteins and reduced lipopolysaccharide-related inflammation by reversing gut dysbiosis in SncaA53T transgenic mice.Our findings showed that the beneficial effect of Lactococcus lactis MG1363-pMG36e-GLP-1 on parkinsonism traits in SncaA53T transgenic mice is mediated by microglial polarization and the reversal of dysbiosis.Collectively,our findings suggest that Lactococcus lactis MG1363-pMG36e-GLP-1 is a promising therapeutic agent for the treatment of Parkinson’s disease.展开更多
Emerging evidence suggests that the gut microbiota is closely associated with the pathological manifestations of multiple neurodegenerative diseases via the gut-brain axis,which refers to the crosstalk between the gut...Emerging evidence suggests that the gut microbiota is closely associated with the pathological manifestations of multiple neurodegenerative diseases via the gut-brain axis,which refers to the crosstalk between the gut and the central nervous system.More importantly,mitochondria have been considered prominent mediators of the interplay between the gut microbiota and the brain.Intestinal microbes may modulate mitochondrial function in the central nervous system to affect the progression of neurodegenerative diseases.Mitochondria are essential for meeting the host’s substantial neuronal metabolic demands,maintaining excitability,and facilitating synaptic transmission.Dysfunctional mitochondria are considered critical hallmarks of various neurodegenerative diseases.Therefore,this review provides novel insights into the intricate roles of gut microbiota-mitochondrial crosstalk in the underlying mechanisms during the progression of neurodegeneration,as well as the existing potential therapeutic strategies for neurodegenerative disorders.These suggest intestinal microbiota-mitochondrial interaction play a crucial role in the occurrence and development of neurodegenerative diseases,and targeting this interaction may be a promising therapeutic approach to neurodegenerative diseases.However,this review found that there was relatively little research on the effect of this crosstalk on other neurodegenerative diseases,such as Huntington’s disease and Multiple sclerosis,and the potential therapeutic strategies were translated into clinical trials,which face many challenges in developing personalized treatment plans based on the unique gut microbiota of different individuals.展开更多
The term“gut microbiota”primarily refers to the ecological community of various microorganisms in the gut,which constitutes the largest microbial community in the human body.Although adequate bowel preparation can i...The term“gut microbiota”primarily refers to the ecological community of various microorganisms in the gut,which constitutes the largest microbial community in the human body.Although adequate bowel preparation can improve the results of colonoscopy,it may interfere with the gut microbiota.Bowel preparation for colonoscopy can lead to transient changes in the gut microbiota,potentially affecting an individual’s health,especially in vulnerable populations,such as patients with inflammatory bowel disease.However,measures such as oral pro-biotics may ameliorate these adverse effects.We focused on the bowel prepa-ration-induced changes in the gut microbiota and host health status,hypothesized the factors influencing these changes,and attempted to identify measures that may reduce dysbiosis,thereby providing more information for individualized bowel preparation for colonoscopy in the future.展开更多
BACKGROUND: Sepsis, a common acute and critical disease, leads to 11 million deaths annually worldwide. Probiotics are living microorganisms that are beneficial to the host and may benefit sepsis outcomes, but their e...BACKGROUND: Sepsis, a common acute and critical disease, leads to 11 million deaths annually worldwide. Probiotics are living microorganisms that are beneficial to the host and may benefit sepsis outcomes, but their effects are stil inconclusive. This study aimed to evaluate the overal eff ect of probiotics on the prognosis of patients with sepsis.DATA RESOURCES: We searched several sources for published/presented studies, including Pub Med, EMBASE, Web of Science, the Cochrane Library and the US National Library of Medicine Clinical Trials Register(www.clinicaltrials.gov) updated through July 30, 2023, to identify all relevant randomized controlled trials(RCTs) or observational studies that assessed the effectiveness of probiotics or synbiotics in patients with sepsis and reported mortality. We focused primarily on mortality during the study period and analyzed secondary outcomes, including 28-day mortality, in-intensive care unit(ICU) mortality and other outcomes.RESULTS: Data from 405 patients in five RCTs and 108 patients in one cohort study were included in the analysis. The overall quality of the studies was satisfactory, but clinical heterogeneity existed. All adult studies reported a tendency for probiotics to reduce the mortality of patients with sepsis, and most studies reported a decreasing trend in the incidence of infectious complications, length of ICU stay and duration of antibiotic use. There was only one RCT involving children.CONCLUSION: Probiotics show promise for improving the prognosis of patients with sepsis, including reducing mortality and the incidence of infectious complications, particularly in adult patients. Despite the limited number of studies, especially in children, these findings will be encouraging for clinical practice in the treatment of sepsis and suggest that gut microbiota-targeted therapy may improve the prognosis of patients with sepsis.展开更多
The gut microbiome comprises a vast community of microbes inhabiting the human alimentary canal,playing a crucial role in various physiological functions.These microbes generally live in harmony with the host;however,...The gut microbiome comprises a vast community of microbes inhabiting the human alimentary canal,playing a crucial role in various physiological functions.These microbes generally live in harmony with the host;however,when dysbiosis occurs,it can contribute to the pathogenesis of diseases,including osteoporosis.Osteoporosis,a systemic skeletal disease characterized by reduced bone mass and increased fracture risk,has attracted significant research attention concerning the role of gut microbes in its development.Advances in molecular biology have highlighted the influence of gut microbiota on osteoporosis through mechanisms involving immunoregulation,modulation of the gut-brain axis,and regulation of the intestinal barrier and nutrient absorption.These microbes can enhance bone mass by inhibiting osteoclast differentiation,inducing apoptosis,reducing bone resorption,and promoting osteoblast proliferation and maturation.Despite these promising findings,the therapeutic effectiveness of targeting gut microbes in osteoporosis requires further investigation.Notably,gut microbiota has been increasingly studied for their potential in early diagnosis,intervention,and as an adjunct therapy for osteoporosis,suggesting a growing utility in improving bone health.Further research is essential to fully elucidate the therapeutic potential and clinical application of gut microbiome modulation in the management of osteoporosis.展开更多
Functional constipation(FC)in elderly individuals is a significant health issue that adversely affects their quality of life,with recent studies indicating a close relationship between this condition and gut microbiot...Functional constipation(FC)in elderly individuals is a significant health issue that adversely affects their quality of life,with recent studies indicating a close relationship between this condition and gut microbiota dysbiosis.This review aims to explore the role of the gut microbiota in FC in elderly individuals,analyze the mechanisms of the gut-brain axis,and evaluate the potential use of microecological agents,including probiotics and prebiotics,in modulating the gut microbiota and alleviating constipation symptoms.By integrating the latest research findings,this study seeks to provide new perspectives and intervention strategies for the management of FC in elderly individuals.展开更多
Probiotic supplementation enhances the abundance of gutassociated Rhodobacteraceae species,critical symbionts contributing to the health and physiological fitness of Litopenaeus vannamei.Understanding the role of Rhod...Probiotic supplementation enhances the abundance of gutassociated Rhodobacteraceae species,critical symbionts contributing to the health and physiological fitness of Litopenaeus vannamei.Understanding the role of Rhodobacteraceae in shaping the shrimp gut microbiota is essential for optimizing probiotic application.This study investigated whether probiotics benefit shrimp health and fitness via the recruitment of Rhodobacteraceae commensals in the gut.Probiotic supplementation significantly enhanced feed conversion efficiency,digestive enzyme activity,and immune responses,thereby promoting shrimp growth.Additionally,probiotics induced pronounced shifts in gut microbial composition,enriched gut Rhodobacteraceae abundance,and reduced community variability,leading to a more stable gut microbiome.Network analysis revealed that the removal of Rhodobacteraceae nodes disrupted gut microbial connectivity more rapidly than the removal of nonRhodobacteraceae nodes,indicating a disproportionate role of Rhodobacteraceae in maintaining network stability.Probiotic supplementation facilitated the migration of Rhodobacteraceae taxa from the aquatic environment to the shrimp gut while reinforcing deterministic selection in gut microbiota assembly.Transcriptomic analysis revealed that up-regulation of amino acid metabolism and NF-κB signaling pathways was positively correlated with Rhodobacteraceae abundance.These findings demonstrate that probiotic supplementation enriches key Rhodobacteraceae taxa,stabilizes gut microbial networks,and enhances host digestive and immune functions,ultimately improving shrimp growth performance.This study provides novel perspectives on the ecological and molecular mechanisms underlying the beneficial effects of probiotics on shrimp fitness.展开更多
Chronic kidney disease(CKD)is a progressive disease with high morbidity and mortality.Disturbed gut microbiota and toxin accumulation are the main pathologic features of CKD.Current treatments are limited to those tha...Chronic kidney disease(CKD)is a progressive disease with high morbidity and mortality.Disturbed gut microbiota and toxin accumulation are the main pathologic features of CKD.Current treatments are limited to those that alleviate renal impairment in CKD patients,but few interventions are available that specifically target the regulatory mechanisms of gut microbiota.In this context,researchers urgently need new approaches that can significantly improve survival time and quality of life in these patients.In this review,we outline the involvement of the gut-kidney axis in kidney injury through disturbances of gut microbiota and dysregulation of endogenous metabolites,as well as the prominent contribution of gut microbiota in the discovery of CKD that can be used to prevent,diagnose,and treat CKD.Next,we describe several major metabolites associated with the host-gut microbiota that arise from the synthesis of microbial nutrient transformations and subsequent interactions with the kidney.Then,we summarize the role and potential targets of a compromised gut barrier in CKD.Finally,we discuss research advances in the prevention and treatments of CKD through probiotics modulation of gut microbiota structure to reduce enterogenous toxins and their maintenance of gut barrier function.A growing body of research suggests that intervention through probiotics may be a new and promising therapeutic strategy for CKD.展开更多
This editorial,inspired by a recent study published in the World Journal of Gastrointestinal Oncology,covers the research findings on microbiota changes in various diseases.In recurrent colorectal polyps,the abundance...This editorial,inspired by a recent study published in the World Journal of Gastrointestinal Oncology,covers the research findings on microbiota changes in various diseases.In recurrent colorectal polyps,the abundances of Klebsiella,Parvimonas,and Clostridium increase,while those of Bifidobacterium and Lactoba-cillus decrease.This dysbiosis may promote the formation and recurrence of polyps.Similar microbial changes have also been observed in colorectal cancer,inflammatory bowel disease,autism spectrum disorder,and metabolic syndrome,indicating the role of increased pathogens and decreased probiotics in these conditions.Regulating the gut microbiota,particularly by increasing probiotic levels,may help prevent polyp recurrence and promote gut health.This microbial intervention strategy holds promise as an adjunctive treatment for patients with colorectal polyps.展开更多
BACKGROUND Food protein-induced enterocolitis syndrome(FPIES)is the most serious type of non-immunoglobulin E(IgE)-mediated food allergic reaction manifesting as sepsis-like symptom,which can lead to shock.Saccharomyc...BACKGROUND Food protein-induced enterocolitis syndrome(FPIES)is the most serious type of non-immunoglobulin E(IgE)-mediated food allergic reaction manifesting as sepsis-like symptom,which can lead to shock.Saccharomyces boulardii(S.boulardii),a probiotic prescribed frequently in clinical settings,has been reported to trigger FPIES in an infant with soy-triggered FPIES.In this report,we describe a new clinical FPIES in which S.boulardii was the sole triggering factor of acute FPIES adverse reaction in seven healthy infants.CASE SUMMARY Seven FPIES cases triggered by only S.boulardii were gathered from 2011 to the present.None of the patients had previously experienced any allergic reaction to cow’s milk,soy,or complementary food.The age of the patients was 4-10-months old,and the symptoms of FPIES developed after ingestion of S.boulardii,which is mostly prescribed for the treatment of gastroenteritis or antibiotic-associated diarrhea.All patients experienced severe repetitive vomiting 1-3 hours after S.boulardii ingestion.Extreme lethargy,marked pallor,and cyanosis were also observed.No IgE-mediated hypersensitivity developed in any patient.Diarrhea was followed by initial intense vomiting in approximately 5-10 hours after S.boulardii ingestion,and only one case showed bloody,purulent,and foul-smelling diarrhea.The patients stabilized quickly,mostly within 6 hours.Symptoms got all improved within 24 hours after discontinuation of S.boulardii.CONCLUSION S.boulardii can be the sole trigger of acute FPIES and be prescribed cautiously even in healthy children without FPIES.展开更多
The prevalence of bacterial digestive diseases in plateau animals has caused considerable losses to the Tibetan live‑stock industry.Therefore,this study aimed to isolate safe lactic acid bacteria(LAB)with beneficial p...The prevalence of bacterial digestive diseases in plateau animals has caused considerable losses to the Tibetan live‑stock industry.Therefore,this study aimed to isolate safe lactic acid bacteria(LAB)with beneficial probiotic proper‑ties to protect yaks from intestinal diseases.After 16S rDNA matching,four strains of Lactobacillus fermentum(A4),Pediococcus pentosaceus(A3.4 and A1.2),and Pediococcus acidilactici(B1.9)were isolated from the intestinal tissues and content of healthy yaks.The results indicated that A4 was more tolerant to bile salt(0.3%),while A3.4 had better stability in an acidic(pH=3.0)environment.The results of the antibacterial activity test suggested that the isolates inhibited most pathogenic bacteria by up to 20%,except for A3.4,which inhibited Pasteurella and Staphylococcus aureus by more than 20%.Moreover,the results of the antioxidant test demonstrated that A4 and A3.4 had potent antioxidant activity.In addition,the drug sensitivity test revealed that the isolates were susceptible to commonly used antibiotics.In terms of safety,the isolates promoted growth,enhanced intestinal development,and protected the intestinal barrier without causing any adverse effects.In conclusion,LAB isolated from yak intestinal contents are potential probiotics with excellent antibacterial properties.展开更多
BACKGROUND Diabetes is an epidemic condition affecting people globally with a high rate of morbidity and mortality.While various pharmacological and non-pharmacological treatment options are used,diabetes is still a n...BACKGROUND Diabetes is an epidemic condition affecting people globally with a high rate of morbidity and mortality.While various pharmacological and non-pharmacological treatment options are used,diabetes is still a non-treatable condition.Constant attempts are made to identify newer therapies that could support better management of the diabetes condition and improve overall quality of life.Numerous studies have supported the potential role of probiotics therapy in the diabetes condition.AIM To evaluate the efficacy of triple probiotic combination on glycaemic,metabolic,oxidative stress,and inflammatory parameters in the diabetic population.METHODS Randomized controlled trials evaluating the efficacy of the triple probiotic combination in diabetic patients were identified.The quality of the studies was evaluated using the PEDro scale while biasness between and within the studies was assessed using the Risk of Bias tool.Meta-analysis was conducted using RevMan software,and sensitivity analysis was performed using OpenMeta Analyst software.The study protocol was registered in PROSPERO(CRD42-024530999).RESULTS Five good-quality clinical trials were included.Low-to-moderate risk of bias was observed.Data from 300 participants were included(150 participants in both groups).Probiotics supplementation significantly improved glycaemic and insulin parameters(glucose level:-23.86 mg/dL;insulin level:-5.02μIU/mL;HOMA-IR:-1.82 score;QUICKI:+0.02 score;HOMA-B:-16.30 score;P<0.05 for all parameters),reduced oxidative stress and improved antioxidant parameters[TAC:+92.55 mmol/L;glutathione(GSH):+40.55μmol/L;nitric oxide(NO):+6.45μmol/L;malondialdehyde(MDA):-0.48μmol/L;hs-CRP:-2.24 mg/L;P<0.05 for all parameters except GSH],and improved lipid parameters(total cholesterol(TC):-3.43 mg/dL;triglycerides(TG):-4.26 mg/dL;low-density lipoprotein:-4.62 mg/dL;very low-density lipoprotein:-0.83 mg/dL;high-density lipoprotein(HDL):+1.83 mg/dL;TC/HDL ratio:-0.25;P<0.05 for HDL and TC/HDL ratio parameters)compared to the control group.CONCLUSION The combination of L.acidophilus,L.casei,and B.bifidum is effective in diabetic patients with cardio/renal complications.Further well-designed studies are warranted to support the results of current research.展开更多
BACKGROUND Depression is a common mental-health disorder worldwide.Several studies have demonstrated the effects of gut microbiota-targeting interventions,such as probiotics,prebiotics,synbiotics,and postbiotics(PPSP)...BACKGROUND Depression is a common mental-health disorder worldwide.Several studies have demonstrated the effects of gut microbiota-targeting interventions,such as probiotics,prebiotics,synbiotics,and postbiotics(PPSP),on depression.AIM To assess the potential benefits of PPSP on patients diagnosed with depressive disorder.METHODS A literature search of the PubMed,Web of Science,and Elsevier Science Direct databases for relevant studies published from database inception to March 2024 was performed.Studies that used a randomized controlled trial design and eva-luated differences in depression between PPSP and placebo were included.Depressive symptoms were assessed using a validated scale.Analysis was performed using Review Manager version 5.4(The Cochrane Collaboration,2020).RESULTS Fourteen studies comprising 906 patients with depressive symptoms were included.PPSP improved depression compared with placebo[SMD:-0.39(95%CI:-0.60 to-0.17);P<0.001].PPSP resulted in significant reductions in Hamilton Depression Rating Scale[MD:-1.72(95%CI:-2.57 to-0.88);P<0.001]and Beck Depression Inventory[MD:-2.69(95%CI:-4.67 to-0.71);P<0.001]scores.Sub-analysis confirmed the antidepressant effects of probiotics on depressive symp-toms[SMD:-0.32(95%CI:-0.48 to-0.16);P<0.001],with prebiotics exerting no apparent effect[SMD:-0.08(95%CI:-0.39 to-0.23);P=0.62],and synbiotics exerting statistically significant benefits[SMD:-1.09(95%CI:-1.45 to-0.73);P<0.001].CONCLUSION PPSP effectively alleviates depressive symptoms,and subgroup analysis supports the benefits of probiotics and synbiotics.Nevertheless,evidence supporting the use of PPSP for the treatment of depression remains insufficient.展开更多
Schizophrenia is a complex neuropsychiatric disorder characterized by cognitive,emotional,and behavioral impairments.The microbiota-gut-brain axis is crucial in its pathophysiology,mediating communication between the ...Schizophrenia is a complex neuropsychiatric disorder characterized by cognitive,emotional,and behavioral impairments.The microbiota-gut-brain axis is crucial in its pathophysiology,mediating communication between the gut and brain through neural,immune,endocrine,and metabolic pathways.Dysbiosis,or an imbalance in gut microbiota,is linked to neuroinflammation,systemic inflam-mation,and neurotransmitter disruptions,all of which contribute to the symp-toms of schizophrenia.Gut microbiota-derived metabolites,such as short-chain fatty acids,influence brain function,including immune responses and neurotrans-mitter synthesis.These findings suggest that microbial imbalances exacerbate schizophrenia,providing a novel perspective on the disorder’s underlying mechanisms.Emerging microbiota-targeted therapies—such as probiotics,prebiotics,dietary interventions,and fecal microbiota trans-plantation—show promise as adjunctive treatments,aiming to restore microbial balance and improve clinical outcomes.While further research is needed,targeting the micro-biota-gut-brain axis offers an innovative approach to schizophrenia management,with the potential to enhance patient outcomes and quality of life.展开更多
Hyperuricemia is a prevalent metabolic disorder resulting from dysregulation of purine metabolism,often accompanied by inflammation.It is characterized by an abnormal elevation in uric acid(UA)levels.In our investigat...Hyperuricemia is a prevalent metabolic disorder resulting from dysregulation of purine metabolism,often accompanied by inflammation.It is characterized by an abnormal elevation in uric acid(UA)levels.In our investigation,the combined treatment with Lactiplantibacillus plantarum DY1 and quercetin suppressed the activity of xanthine oxidase and adenosine deaminase,decreased the levels of UA,tumor necrosis factor alpha(TNF-α)and interleukin 1β(IL-β),downregulated gene expression of urate transporter 1(URAT1)and glucose transporter 9(GLUT9),and upregulated organic anion transporter 1(OAT1)and ATP-binding cassette transporter subfamily G member 2(ABCG2).The combination increased the abundance of Lactobacillus and decreased the abundance of norank_f_norank_o__Clostridia_UCG-014 and Roseburia.Metabolomics analysis revealed that the combination of probiotics and quercetin exhibited distinct metabolic pathways compared to their individual administrations.When compared to probiotics alone,the combination led to alterations in glutathione metabolism(oxidized glutathione and glutathione)as well as sphingolipid metabolism(sphingosine and sphinganine).When compared to quercetin alone,the combination resulted in variations in tryptophan metabolism(indole-3-acetamide,5-hydroxy-L-tryptophan,indoleacetaldehyde,3-(3-indolyl)-2-oxopropanoic acid,3-indoleacetic acid and 3-methylindole)along with purine metabolism(UA,xanthosine,cyclic adenosine monophosphate(cAMP),adenosine diphosphate(ADP)and adenosine monophosphate(AMP)).The subsequent fecal microbiota transplantation proved that the effect of the combination on reducing UA levels was mediated by the gut microbiota.Therefore,this new combination can be considered a promising adjuvant therapy capable of synergistically alleviating hyperuricemia.展开更多
Background Coccidiosis,caused by Eimeria parasites,is a major enteric disease in poultry,significantly impacting animal health,production performance,and welfare.This disease imposes a substantial economic burden,cost...Background Coccidiosis,caused by Eimeria parasites,is a major enteric disease in poultry,significantly impacting animal health,production performance,and welfare.This disease imposes a substantial economic burden,costing the global poultry industry up to$13 billion annually.However,effective mitigation strategies for coccidiosis remain elusive.While different chicken breeds exhibit varying resistance to coccidiosis,no commensal bacteria have been directly linked to this resistance.Methods To assess relative resistance of different breeds to coccidiosis,10-day-old Fayoumi M5.1,Leghorn Ghs6,and Cobb chickens were challenged with 50,000 sporulated Eimeria maxima oocysts or mock-infected.Body weight changes,small intestinal lesions,and fecal oocyst shedding were evaluated on d 17.Ileal and cecal digesta were collected from individual animals on d 17 and subjected to microbiome analysis using 16S rRNA gene sequencing.Results Fayoumi M5.1 chickens showed the lowest growth retardation,intestinal lesion score,fecal oocyst shedding,and pathobiont proliferation compared to Ghs6 and Cobb chickens.The intestinal microbiota of M5.1 chickens also differed markedly from the other two breeds under both healthy and coccidiosis conditions.Notably,group A Lactobacillus and Ligilactobacillus salivarius were the least prevalent in both the ileum and cecum of healthy M5.1 chickens,but became highly enriched and comparable to Ghs6 and Cobb chickens in response to coccidiosis.Conversely,Weissella,Staphylococcus gallinarum,and Enterococcus durans/hirae were more abundant in the ileum of healthy M5.1 chickens than in the other two breeds.Despite being reduced by Eimeria,these bacteria retained higher abundance in M5.1 chickens compared to the other breeds.Conclusions Fayoumi M5.1 chickens exhibit greater resistance to coccidiosis than Leghorn Ghs6 layers and Cobb broilers.Several commensal bacteria,including group A Lactobacillus,L.salivarius,Weissella,S.gallinarum,and E.durans/hirae,are differentially enriched in Fayoumi M5.1 chickens with strong correlation with coccidiosis resistance.These bacteria hold potential as probiotics for coccidiosis mitigation.展开更多
文摘Probiotical cell fragments (PCFs) are structural components of the probiotic cell lysate(s) and exhibit similar beneficial effects on the host as live probiotic bacteria. With cell fragment technology (CFT?), the structural fragments are isolated and purified from live probiotic cells. While observed to be strain-dependent as in the case of live probiotics, orally administered PCFs demonstrated a broad spectrum of immune modulation functions;anti-allergy;anti-inflammation;anti-bacterial and anti-viral properties;anti-mutagenic;and radioprotective and detoxification abilities in humans and animals. The PCFs mechanisms of action include events of motifs of cell wall peptidoglycans, DNA motifs, nucleotide containing components, lipoteichoic acids (LPAs), surface layer (S-layer) proteins, and cytoplasmic proteins. Different immunological in vivo-in vitro tests have shown that PCFs, essentially, have the ability to stimulate the macrophages, and induce cytokines such as interleukins, tumor necrosis factors (TNFs), interferons (IFNs), and natural killer (NK) cells. PCFs may be used as ingredients for foods and beverages or as nutritional supplements with long term stability and shelf-life up to 5 years. PCFs may also be used as health restorative ingredients in cosmetic products. The outcome of probiotics CFT? stands as an advantage to the food and pharmaceutical industries, regarding the formulation of novel products with unadulterated sensory characteristics of origin. Hence, PCFs are being characterized here as “novel nutraceutical ingredients” for health maintenance in both humans and animals.
文摘The evidence in this paper indicates that the alarming increase of common allergies can be reduced by the intake of particular “probiotics” or “paraprobiotics” along with food. This appears to build a consensus in the pharmaceutical and food communities about the role of probiotics in the prevention and treatments of common allergies. Food allergy is one of the common allergies, defined as an adverse health effect arising from a specific immune response that occurs reproducibly on exposure to a given food. Improving the digestion of foods and maintaining a healthy gastrointestinal (GI) tract is certainly critical to controlling food allergens. Therefore, the association between a leaky gut or an impaired intestinal permeability and food-allergenic reactions is explained. Gluten has been found to be somehow a justification for protein allergy, and should, therefore, be avoided by people with celiac disease. In several, in vitro models, surface layer (S- layer) proteins of selective paraprobiotics have shown potential in alleviating food allergies and intestinal disorders. Notably, lactobacilli paraprobiotics have proven to be the immediate immunomodulators against common allergies and other diseases, including viral (flu, hepatitis C), bacterial (bronchitis), asthma, chronic fatigue, fibromyalgia, gastrointestinal distress, and autism disorders in humans.
基金financial support from the Postdoctoral Fellowship Program of China Postdoctoral Science Foundation(GZC20230718)。
文摘The interplay between gut microbiota and host health has attracted significant interest in the animal science community.Maintaining gut microbiota homeostasis by supplementing probiotics to treat clinical conditions like calf diarrhea is an emerging area of research nowadays because of increased concerns regarding antimicrobial resistance(AMR)and drug residues in animal products.Probiotics reduce the incidence of calf diarrhea by increasing the gut microbiota diversity and richness with more commensal bacteria such as Lactobacillus and Bifidobacterium that produce antimicrobial compounds,as well as modulating the immune response by increasing cytokines,Interleukin-2(IL-2),IL-4,IL-6,IL-10,and reducing tumor necrosis factor-α(TNF-α),by increasing production of antibodies,especially immunoglobulin E(Ig E),also Ig G,differentiating naive Th lymphocytes(Tho)into Th1,hence stimulate innate immunity and prime the adaptive immune response.Specific probiotic strains of bacteria and yeast(Saccharomyces cerevisiae)derived probiotics maintain the integrity of the intestinal barrier.In this review,data are being organized to address the role of probiotics in treating calf diarrhea by modulating gut microbiota and stimulating an immune response against notorious pathogens,to present animal and veterinary scientists and nutritionists with a new concept to treat infectious diseases from the perspective of the gut microbiota,increasing animal health,performance,and welfare.In conclusion,health status and gut microbiome are strongly interlinked.Research data indicated a significant reduction in the incidence of diarrhea after probiotic administration.If interrelations between probiotics and existing gut microbiota are explored more quantitatively,novel antibiotic substitutes can emerge in the future.
基金funded by the Ministerio de Ciencia e Innovación Spain(PID2020-113388RB-I00,AEI/10.13039/501100011033)Consellería de Innovación,Universidades,Ciencia y Sociedad Digital,Generalitat Valenciana(CIPROM/2021/082)+2 种基金co-funded with European Regional Development Funds(ERDF)(PID2020-113388RB-I00,and CIPROM/2021/082)PID2022-136874OB-C33 from MCIN/AEI/10.13039/501100011033by the European Union NextGenerationEU/PRTR(to VF).
文摘The mechanisms leading to neurological and neurodegenerative diseases are not completely known,and new,more effective,therapeutic treatments are necessary for most neurological pathologies.The treatment of neurological and neurodegenerative diseases is complicated due to the blood-brain barrier,which makes it difficult for drugs to access the brain areas in which they must act to improve the pathology.A tool that can help to overcome this difficulty is the use of extracellular vesicles,which can easily cross the blood-brain barrier.The extracellular vesicles are considered a main way of communication between the brain and the rest of the body,with important implications for the physiopathology and therapy of neurological diseases.In recent years,the involvement of microbiota in many neurological pathologies,as well as its possible therapeutic role,has also become evident.A key mediator in the pathologic and beneficial effects of microbiota seems to be the bacterial extracellular vesicles.There is an important communication between the brain and the intestinal microbiota(the gut-brain axis),by which the microbiota influences brain function,impacts on mental health,and plays a role in different neurological and neurodegenerative diseases.The identification of the mechanisms involved in this gut-brain axis is essential to understanding the mechanisms of neurological pathologies and to developing more effective treatments for these diseases.Bacterial extracellular vesicles would play a relevant role in these processes.This review compiles the recent information and evidence on the role of bacterial extracellular vesicles in brain pathologies and on the therapeutic utility of bacterial extracellular vesicles in neurological and neurodegenerative diseases.One advantage of bacterial extracellular vesicles compared to extracellular vesicles derived from other cell types,such as stem cells,is that bacterial extracellular vesicles are generally easier to produce and modify.Bacterial extracellular vesicles may be easily modified to target a specific pathology and/or to enhance its therapeutic efficacy.Although the studies are still scarce,they open a wide field of possibilities for future studies,which will lead to a deeper understanding of the role of microbiota and bacterial extracellular vesicles in neurological pathologies and the underlying mechanisms,as well as to the development of new treatments based on the use of bacterial extracellular vesicles in neurological diseases.
基金supported by grants from the Jiangxi Provincial Natural Science Foundation,No.20242BAB26134(to XF)the National Natural Science Foundation of China,Nos.82060638(to TC),82060222(to XF),82460237(to XF)+1 种基金the Major Disciplines of Academic and Technical Leaders Project of Jiangxi Province,Nos.20194BCJ22032(to TC),20213BCJL22049(to XF)Science and Technology Plan of Jiangxi Health Planning Committee,No.202210390(to XF).
文摘Parkinson’s disease is characterized by synucleinopathy-associated neurodegeneration.Previous studies have shown that glucagon-like peptide-1(GLP-1)has beneficial effects in a mouse model of Parkinson’s disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.However,the effect of GLP-1 on intrinsic synuclein malfunction remains unclear.In this study,we investigated the effect of Lactococcus lactis MG1363-pMG36e-GLP-1 on parkinsonism in SncaA53T transgenic mice and explored the underlying mechanisms.Our data showed that Lactococcus lactis MG1363-pMG36e-GLP-1 inhibited dopaminergic neuronal death,reduced pathological aggregation ofα-synuclein,and decreased movement disorders in SncaA53T transgenic mice.Furthermore,Lactococcus lactis MG1363-pMG36e-GLP-1 downregulated lipopolysaccharide-related inflammation,reduced cerebral activation of microglia and astrocytes,and promoted cell survival via the GLP-1 receptor/PI3K/Akt pathway in the substantia nigra.Additionally,Lactococcus lactis MG1363-pMG36e-GLP-1 decreased serum levels of pro-inflammatory molecules including lipopolysaccharide,lipopolysaccharide binding protein,interleukin-1β,and interleukin-6.Gut histopathology and western blotting further revealed that Lactococcus lactis MG1363-pMG36e-GLP-1 increased the expression of gut integrity-related proteins and reduced lipopolysaccharide-related inflammation by reversing gut dysbiosis in SncaA53T transgenic mice.Our findings showed that the beneficial effect of Lactococcus lactis MG1363-pMG36e-GLP-1 on parkinsonism traits in SncaA53T transgenic mice is mediated by microglial polarization and the reversal of dysbiosis.Collectively,our findings suggest that Lactococcus lactis MG1363-pMG36e-GLP-1 is a promising therapeutic agent for the treatment of Parkinson’s disease.
基金supported by General Program of National Natural Science Foundation of China,No.82370986(to LAW)Shaanxi Provincial NaturalScience Foundation Key Project,No.2023-JC-ZD-56(to SS).
文摘Emerging evidence suggests that the gut microbiota is closely associated with the pathological manifestations of multiple neurodegenerative diseases via the gut-brain axis,which refers to the crosstalk between the gut and the central nervous system.More importantly,mitochondria have been considered prominent mediators of the interplay between the gut microbiota and the brain.Intestinal microbes may modulate mitochondrial function in the central nervous system to affect the progression of neurodegenerative diseases.Mitochondria are essential for meeting the host’s substantial neuronal metabolic demands,maintaining excitability,and facilitating synaptic transmission.Dysfunctional mitochondria are considered critical hallmarks of various neurodegenerative diseases.Therefore,this review provides novel insights into the intricate roles of gut microbiota-mitochondrial crosstalk in the underlying mechanisms during the progression of neurodegeneration,as well as the existing potential therapeutic strategies for neurodegenerative disorders.These suggest intestinal microbiota-mitochondrial interaction play a crucial role in the occurrence and development of neurodegenerative diseases,and targeting this interaction may be a promising therapeutic approach to neurodegenerative diseases.However,this review found that there was relatively little research on the effect of this crosstalk on other neurodegenerative diseases,such as Huntington’s disease and Multiple sclerosis,and the potential therapeutic strategies were translated into clinical trials,which face many challenges in developing personalized treatment plans based on the unique gut microbiota of different individuals.
文摘The term“gut microbiota”primarily refers to the ecological community of various microorganisms in the gut,which constitutes the largest microbial community in the human body.Although adequate bowel preparation can improve the results of colonoscopy,it may interfere with the gut microbiota.Bowel preparation for colonoscopy can lead to transient changes in the gut microbiota,potentially affecting an individual’s health,especially in vulnerable populations,such as patients with inflammatory bowel disease.However,measures such as oral pro-biotics may ameliorate these adverse effects.We focused on the bowel prepa-ration-induced changes in the gut microbiota and host health status,hypothesized the factors influencing these changes,and attempted to identify measures that may reduce dysbiosis,thereby providing more information for individualized bowel preparation for colonoscopy in the future.
基金supported by the National High Level Hospital Clinical Research Funding (2022-PUMCH-B-109)Chinese Academy of Medical Science Innovation Fund for Medical Sciences (CIFMS)(2021-I2M-1-020)。
文摘BACKGROUND: Sepsis, a common acute and critical disease, leads to 11 million deaths annually worldwide. Probiotics are living microorganisms that are beneficial to the host and may benefit sepsis outcomes, but their effects are stil inconclusive. This study aimed to evaluate the overal eff ect of probiotics on the prognosis of patients with sepsis.DATA RESOURCES: We searched several sources for published/presented studies, including Pub Med, EMBASE, Web of Science, the Cochrane Library and the US National Library of Medicine Clinical Trials Register(www.clinicaltrials.gov) updated through July 30, 2023, to identify all relevant randomized controlled trials(RCTs) or observational studies that assessed the effectiveness of probiotics or synbiotics in patients with sepsis and reported mortality. We focused primarily on mortality during the study period and analyzed secondary outcomes, including 28-day mortality, in-intensive care unit(ICU) mortality and other outcomes.RESULTS: Data from 405 patients in five RCTs and 108 patients in one cohort study were included in the analysis. The overall quality of the studies was satisfactory, but clinical heterogeneity existed. All adult studies reported a tendency for probiotics to reduce the mortality of patients with sepsis, and most studies reported a decreasing trend in the incidence of infectious complications, length of ICU stay and duration of antibiotic use. There was only one RCT involving children.CONCLUSION: Probiotics show promise for improving the prognosis of patients with sepsis, including reducing mortality and the incidence of infectious complications, particularly in adult patients. Despite the limited number of studies, especially in children, these findings will be encouraging for clinical practice in the treatment of sepsis and suggest that gut microbiota-targeted therapy may improve the prognosis of patients with sepsis.
文摘The gut microbiome comprises a vast community of microbes inhabiting the human alimentary canal,playing a crucial role in various physiological functions.These microbes generally live in harmony with the host;however,when dysbiosis occurs,it can contribute to the pathogenesis of diseases,including osteoporosis.Osteoporosis,a systemic skeletal disease characterized by reduced bone mass and increased fracture risk,has attracted significant research attention concerning the role of gut microbes in its development.Advances in molecular biology have highlighted the influence of gut microbiota on osteoporosis through mechanisms involving immunoregulation,modulation of the gut-brain axis,and regulation of the intestinal barrier and nutrient absorption.These microbes can enhance bone mass by inhibiting osteoclast differentiation,inducing apoptosis,reducing bone resorption,and promoting osteoblast proliferation and maturation.Despite these promising findings,the therapeutic effectiveness of targeting gut microbes in osteoporosis requires further investigation.Notably,gut microbiota has been increasingly studied for their potential in early diagnosis,intervention,and as an adjunct therapy for osteoporosis,suggesting a growing utility in improving bone health.Further research is essential to fully elucidate the therapeutic potential and clinical application of gut microbiome modulation in the management of osteoporosis.
文摘Functional constipation(FC)in elderly individuals is a significant health issue that adversely affects their quality of life,with recent studies indicating a close relationship between this condition and gut microbiota dysbiosis.This review aims to explore the role of the gut microbiota in FC in elderly individuals,analyze the mechanisms of the gut-brain axis,and evaluate the potential use of microecological agents,including probiotics and prebiotics,in modulating the gut microbiota and alleviating constipation symptoms.By integrating the latest research findings,this study seeks to provide new perspectives and intervention strategies for the management of FC in elderly individuals.
基金supported by the National Natural Science Foundation of China(32371596)Key Natural Science Foundation of Zhejiang Province(Z25C030002)+2 种基金Science and Technology Innovation Yongjiang 2035 Key Research and Development Project of Ningbo(2024Z279)One Health Interdisciplinary Research Project(HZ202404)K.C.Wong Magna Fund in Ningbo University。
文摘Probiotic supplementation enhances the abundance of gutassociated Rhodobacteraceae species,critical symbionts contributing to the health and physiological fitness of Litopenaeus vannamei.Understanding the role of Rhodobacteraceae in shaping the shrimp gut microbiota is essential for optimizing probiotic application.This study investigated whether probiotics benefit shrimp health and fitness via the recruitment of Rhodobacteraceae commensals in the gut.Probiotic supplementation significantly enhanced feed conversion efficiency,digestive enzyme activity,and immune responses,thereby promoting shrimp growth.Additionally,probiotics induced pronounced shifts in gut microbial composition,enriched gut Rhodobacteraceae abundance,and reduced community variability,leading to a more stable gut microbiome.Network analysis revealed that the removal of Rhodobacteraceae nodes disrupted gut microbial connectivity more rapidly than the removal of nonRhodobacteraceae nodes,indicating a disproportionate role of Rhodobacteraceae in maintaining network stability.Probiotic supplementation facilitated the migration of Rhodobacteraceae taxa from the aquatic environment to the shrimp gut while reinforcing deterministic selection in gut microbiota assembly.Transcriptomic analysis revealed that up-regulation of amino acid metabolism and NF-κB signaling pathways was positively correlated with Rhodobacteraceae abundance.These findings demonstrate that probiotic supplementation enriches key Rhodobacteraceae taxa,stabilizes gut microbial networks,and enhances host digestive and immune functions,ultimately improving shrimp growth performance.This study provides novel perspectives on the ecological and molecular mechanisms underlying the beneficial effects of probiotics on shrimp fitness.
基金supported by the Shandong Taishan Industry Leading Talent Project(LJNY202101)Fundamental Research Funds for the Central Universities(202313041)Qingdao Postdoctoral Applied Research Project(QDBSH20220202059).
文摘Chronic kidney disease(CKD)is a progressive disease with high morbidity and mortality.Disturbed gut microbiota and toxin accumulation are the main pathologic features of CKD.Current treatments are limited to those that alleviate renal impairment in CKD patients,but few interventions are available that specifically target the regulatory mechanisms of gut microbiota.In this context,researchers urgently need new approaches that can significantly improve survival time and quality of life in these patients.In this review,we outline the involvement of the gut-kidney axis in kidney injury through disturbances of gut microbiota and dysregulation of endogenous metabolites,as well as the prominent contribution of gut microbiota in the discovery of CKD that can be used to prevent,diagnose,and treat CKD.Next,we describe several major metabolites associated with the host-gut microbiota that arise from the synthesis of microbial nutrient transformations and subsequent interactions with the kidney.Then,we summarize the role and potential targets of a compromised gut barrier in CKD.Finally,we discuss research advances in the prevention and treatments of CKD through probiotics modulation of gut microbiota structure to reduce enterogenous toxins and their maintenance of gut barrier function.A growing body of research suggests that intervention through probiotics may be a new and promising therapeutic strategy for CKD.
文摘This editorial,inspired by a recent study published in the World Journal of Gastrointestinal Oncology,covers the research findings on microbiota changes in various diseases.In recurrent colorectal polyps,the abundances of Klebsiella,Parvimonas,and Clostridium increase,while those of Bifidobacterium and Lactoba-cillus decrease.This dysbiosis may promote the formation and recurrence of polyps.Similar microbial changes have also been observed in colorectal cancer,inflammatory bowel disease,autism spectrum disorder,and metabolic syndrome,indicating the role of increased pathogens and decreased probiotics in these conditions.Regulating the gut microbiota,particularly by increasing probiotic levels,may help prevent polyp recurrence and promote gut health.This microbial intervention strategy holds promise as an adjunctive treatment for patients with colorectal polyps.
基金Supported by The Keimyung University Dongsan Medical Center in 2006.
文摘BACKGROUND Food protein-induced enterocolitis syndrome(FPIES)is the most serious type of non-immunoglobulin E(IgE)-mediated food allergic reaction manifesting as sepsis-like symptom,which can lead to shock.Saccharomyces boulardii(S.boulardii),a probiotic prescribed frequently in clinical settings,has been reported to trigger FPIES in an infant with soy-triggered FPIES.In this report,we describe a new clinical FPIES in which S.boulardii was the sole triggering factor of acute FPIES adverse reaction in seven healthy infants.CASE SUMMARY Seven FPIES cases triggered by only S.boulardii were gathered from 2011 to the present.None of the patients had previously experienced any allergic reaction to cow’s milk,soy,or complementary food.The age of the patients was 4-10-months old,and the symptoms of FPIES developed after ingestion of S.boulardii,which is mostly prescribed for the treatment of gastroenteritis or antibiotic-associated diarrhea.All patients experienced severe repetitive vomiting 1-3 hours after S.boulardii ingestion.Extreme lethargy,marked pallor,and cyanosis were also observed.No IgE-mediated hypersensitivity developed in any patient.Diarrhea was followed by initial intense vomiting in approximately 5-10 hours after S.boulardii ingestion,and only one case showed bloody,purulent,and foul-smelling diarrhea.The patients stabilized quickly,mostly within 6 hours.Symptoms got all improved within 24 hours after discontinuation of S.boulardii.CONCLUSION S.boulardii can be the sole trigger of acute FPIES and be prescribed cautiously even in healthy children without FPIES.
基金supported by the Key Project of Tibet Autonomous Region(XZ202001ZY0044NXZ202101ZD0002N-05).
文摘The prevalence of bacterial digestive diseases in plateau animals has caused considerable losses to the Tibetan live‑stock industry.Therefore,this study aimed to isolate safe lactic acid bacteria(LAB)with beneficial probiotic proper‑ties to protect yaks from intestinal diseases.After 16S rDNA matching,four strains of Lactobacillus fermentum(A4),Pediococcus pentosaceus(A3.4 and A1.2),and Pediococcus acidilactici(B1.9)were isolated from the intestinal tissues and content of healthy yaks.The results indicated that A4 was more tolerant to bile salt(0.3%),while A3.4 had better stability in an acidic(pH=3.0)environment.The results of the antibacterial activity test suggested that the isolates inhibited most pathogenic bacteria by up to 20%,except for A3.4,which inhibited Pasteurella and Staphylococcus aureus by more than 20%.Moreover,the results of the antioxidant test demonstrated that A4 and A3.4 had potent antioxidant activity.In addition,the drug sensitivity test revealed that the isolates were susceptible to commonly used antibiotics.In terms of safety,the isolates promoted growth,enhanced intestinal development,and protected the intestinal barrier without causing any adverse effects.In conclusion,LAB isolated from yak intestinal contents are potential probiotics with excellent antibacterial properties.
文摘BACKGROUND Diabetes is an epidemic condition affecting people globally with a high rate of morbidity and mortality.While various pharmacological and non-pharmacological treatment options are used,diabetes is still a non-treatable condition.Constant attempts are made to identify newer therapies that could support better management of the diabetes condition and improve overall quality of life.Numerous studies have supported the potential role of probiotics therapy in the diabetes condition.AIM To evaluate the efficacy of triple probiotic combination on glycaemic,metabolic,oxidative stress,and inflammatory parameters in the diabetic population.METHODS Randomized controlled trials evaluating the efficacy of the triple probiotic combination in diabetic patients were identified.The quality of the studies was evaluated using the PEDro scale while biasness between and within the studies was assessed using the Risk of Bias tool.Meta-analysis was conducted using RevMan software,and sensitivity analysis was performed using OpenMeta Analyst software.The study protocol was registered in PROSPERO(CRD42-024530999).RESULTS Five good-quality clinical trials were included.Low-to-moderate risk of bias was observed.Data from 300 participants were included(150 participants in both groups).Probiotics supplementation significantly improved glycaemic and insulin parameters(glucose level:-23.86 mg/dL;insulin level:-5.02μIU/mL;HOMA-IR:-1.82 score;QUICKI:+0.02 score;HOMA-B:-16.30 score;P<0.05 for all parameters),reduced oxidative stress and improved antioxidant parameters[TAC:+92.55 mmol/L;glutathione(GSH):+40.55μmol/L;nitric oxide(NO):+6.45μmol/L;malondialdehyde(MDA):-0.48μmol/L;hs-CRP:-2.24 mg/L;P<0.05 for all parameters except GSH],and improved lipid parameters(total cholesterol(TC):-3.43 mg/dL;triglycerides(TG):-4.26 mg/dL;low-density lipoprotein:-4.62 mg/dL;very low-density lipoprotein:-0.83 mg/dL;high-density lipoprotein(HDL):+1.83 mg/dL;TC/HDL ratio:-0.25;P<0.05 for HDL and TC/HDL ratio parameters)compared to the control group.CONCLUSION The combination of L.acidophilus,L.casei,and B.bifidum is effective in diabetic patients with cardio/renal complications.Further well-designed studies are warranted to support the results of current research.
文摘BACKGROUND Depression is a common mental-health disorder worldwide.Several studies have demonstrated the effects of gut microbiota-targeting interventions,such as probiotics,prebiotics,synbiotics,and postbiotics(PPSP),on depression.AIM To assess the potential benefits of PPSP on patients diagnosed with depressive disorder.METHODS A literature search of the PubMed,Web of Science,and Elsevier Science Direct databases for relevant studies published from database inception to March 2024 was performed.Studies that used a randomized controlled trial design and eva-luated differences in depression between PPSP and placebo were included.Depressive symptoms were assessed using a validated scale.Analysis was performed using Review Manager version 5.4(The Cochrane Collaboration,2020).RESULTS Fourteen studies comprising 906 patients with depressive symptoms were included.PPSP improved depression compared with placebo[SMD:-0.39(95%CI:-0.60 to-0.17);P<0.001].PPSP resulted in significant reductions in Hamilton Depression Rating Scale[MD:-1.72(95%CI:-2.57 to-0.88);P<0.001]and Beck Depression Inventory[MD:-2.69(95%CI:-4.67 to-0.71);P<0.001]scores.Sub-analysis confirmed the antidepressant effects of probiotics on depressive symp-toms[SMD:-0.32(95%CI:-0.48 to-0.16);P<0.001],with prebiotics exerting no apparent effect[SMD:-0.08(95%CI:-0.39 to-0.23);P=0.62],and synbiotics exerting statistically significant benefits[SMD:-1.09(95%CI:-1.45 to-0.73);P<0.001].CONCLUSION PPSP effectively alleviates depressive symptoms,and subgroup analysis supports the benefits of probiotics and synbiotics.Nevertheless,evidence supporting the use of PPSP for the treatment of depression remains insufficient.
文摘Schizophrenia is a complex neuropsychiatric disorder characterized by cognitive,emotional,and behavioral impairments.The microbiota-gut-brain axis is crucial in its pathophysiology,mediating communication between the gut and brain through neural,immune,endocrine,and metabolic pathways.Dysbiosis,or an imbalance in gut microbiota,is linked to neuroinflammation,systemic inflam-mation,and neurotransmitter disruptions,all of which contribute to the symp-toms of schizophrenia.Gut microbiota-derived metabolites,such as short-chain fatty acids,influence brain function,including immune responses and neurotrans-mitter synthesis.These findings suggest that microbial imbalances exacerbate schizophrenia,providing a novel perspective on the disorder’s underlying mechanisms.Emerging microbiota-targeted therapies—such as probiotics,prebiotics,dietary interventions,and fecal microbiota trans-plantation—show promise as adjunctive treatments,aiming to restore microbial balance and improve clinical outcomes.While further research is needed,targeting the micro-biota-gut-brain axis offers an innovative approach to schizophrenia management,with the potential to enhance patient outcomes and quality of life.
基金supported by National Science and Technology Fundamental Resources Investigation Program of China(2019FY100700).
文摘Hyperuricemia is a prevalent metabolic disorder resulting from dysregulation of purine metabolism,often accompanied by inflammation.It is characterized by an abnormal elevation in uric acid(UA)levels.In our investigation,the combined treatment with Lactiplantibacillus plantarum DY1 and quercetin suppressed the activity of xanthine oxidase and adenosine deaminase,decreased the levels of UA,tumor necrosis factor alpha(TNF-α)and interleukin 1β(IL-β),downregulated gene expression of urate transporter 1(URAT1)and glucose transporter 9(GLUT9),and upregulated organic anion transporter 1(OAT1)and ATP-binding cassette transporter subfamily G member 2(ABCG2).The combination increased the abundance of Lactobacillus and decreased the abundance of norank_f_norank_o__Clostridia_UCG-014 and Roseburia.Metabolomics analysis revealed that the combination of probiotics and quercetin exhibited distinct metabolic pathways compared to their individual administrations.When compared to probiotics alone,the combination led to alterations in glutathione metabolism(oxidized glutathione and glutathione)as well as sphingolipid metabolism(sphingosine and sphinganine).When compared to quercetin alone,the combination resulted in variations in tryptophan metabolism(indole-3-acetamide,5-hydroxy-L-tryptophan,indoleacetaldehyde,3-(3-indolyl)-2-oxopropanoic acid,3-indoleacetic acid and 3-methylindole)along with purine metabolism(UA,xanthosine,cyclic adenosine monophosphate(cAMP),adenosine diphosphate(ADP)and adenosine monophosphate(AMP)).The subsequent fecal microbiota transplantation proved that the effect of the combination on reducing UA levels was mediated by the gut microbiota.Therefore,this new combination can be considered a promising adjuvant therapy capable of synergistically alleviating hyperuricemia.
基金funded by the USDA National Institute of Food and Agriculture grants(2022-67016-37208 and 2024-67016-42415)the Ralph F.and Leila W.Boulware Endowment Fund,Oklahoma Agricultural Experiment Station Project H-3268+1 种基金Iowa Agriculture and Home Economics Experiment Station Project IOW05620supported by two separate USDA National Institute of Food and Agriculture Predoctoral Fellowship grants(2024-67011-42944 and 2021-67034-35184).
文摘Background Coccidiosis,caused by Eimeria parasites,is a major enteric disease in poultry,significantly impacting animal health,production performance,and welfare.This disease imposes a substantial economic burden,costing the global poultry industry up to$13 billion annually.However,effective mitigation strategies for coccidiosis remain elusive.While different chicken breeds exhibit varying resistance to coccidiosis,no commensal bacteria have been directly linked to this resistance.Methods To assess relative resistance of different breeds to coccidiosis,10-day-old Fayoumi M5.1,Leghorn Ghs6,and Cobb chickens were challenged with 50,000 sporulated Eimeria maxima oocysts or mock-infected.Body weight changes,small intestinal lesions,and fecal oocyst shedding were evaluated on d 17.Ileal and cecal digesta were collected from individual animals on d 17 and subjected to microbiome analysis using 16S rRNA gene sequencing.Results Fayoumi M5.1 chickens showed the lowest growth retardation,intestinal lesion score,fecal oocyst shedding,and pathobiont proliferation compared to Ghs6 and Cobb chickens.The intestinal microbiota of M5.1 chickens also differed markedly from the other two breeds under both healthy and coccidiosis conditions.Notably,group A Lactobacillus and Ligilactobacillus salivarius were the least prevalent in both the ileum and cecum of healthy M5.1 chickens,but became highly enriched and comparable to Ghs6 and Cobb chickens in response to coccidiosis.Conversely,Weissella,Staphylococcus gallinarum,and Enterococcus durans/hirae were more abundant in the ileum of healthy M5.1 chickens than in the other two breeds.Despite being reduced by Eimeria,these bacteria retained higher abundance in M5.1 chickens compared to the other breeds.Conclusions Fayoumi M5.1 chickens exhibit greater resistance to coccidiosis than Leghorn Ghs6 layers and Cobb broilers.Several commensal bacteria,including group A Lactobacillus,L.salivarius,Weissella,S.gallinarum,and E.durans/hirae,are differentially enriched in Fayoumi M5.1 chickens with strong correlation with coccidiosis resistance.These bacteria hold potential as probiotics for coccidiosis mitigation.
